



FILE COPY

October 23, 2006

J. Martin Carroll
President and CEO
Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
Ridgefield, CT 06877

Dear Mr. Carroll:

Your petition requesting the Food and Drug Administration to refrain temporarily from taking action to remove the chlorofluorocarbon containing metered-doses ipratropium bromide and albuterol sulfate, in combination, administered by oral inhalation for human use (COMBIVENT) from the list of essential uses of CFCs, was received by this office on 10/23/2006. It was assigned docket number 2006P-0428/CP 1 and it was filed on 10/23/2006. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe
Division of Dockets Management
Office of Management Programs
Office of Management

2006P-0428

ACK 1